WO2000070017A3 - Procedes utilisant des composes de fab i et des composes modulant l'activite de fab i - Google Patents

Procedes utilisant des composes de fab i et des composes modulant l'activite de fab i Download PDF

Info

Publication number
WO2000070017A3
WO2000070017A3 PCT/US2000/012104 US0012104W WO0070017A3 WO 2000070017 A3 WO2000070017 A3 WO 2000070017A3 US 0012104 W US0012104 W US 0012104W WO 0070017 A3 WO0070017 A3 WO 0070017A3
Authority
WO
WIPO (PCT)
Prior art keywords
fab
disclosed
methods
polypeptides
activity
Prior art date
Application number
PCT/US2000/012104
Other languages
English (en)
Other versions
WO2000070017A2 (fr
Inventor
Walter E Dewolf
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Walter E Dewolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc, Walter E Dewolf filed Critical Smithkline Beecham Corp
Priority to JP2000618423A priority Critical patent/JP2002544291A/ja
Priority to EP00935862A priority patent/EP1180164A4/fr
Publication of WO2000070017A2 publication Critical patent/WO2000070017A2/fr
Publication of WO2000070017A3 publication Critical patent/WO2000070017A3/fr
Priority to US10/888,524 priority patent/US20050112713A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des polypeptides de FAB I procaryote et des polynucléotides (ADN, ARN) codant pour un tel FAB I ainsi qu'un procédé permettant de produire de tels polypeptides au moyen de techniques recombinantes. Elle concerne aussi des procédés d'utilisation d'un tel FAB I destinés au traitement d'infections, telles que des infections bactériennes, ainsi que des antagonistes contre un tel FAB I et leur utilisation comme principe actif dans le traitement d'infections telles que les infections à staphylocoques. L'invention concerne aussi des tests diagnostics de détection de maladies, dues à la présence de séquences d'acides nucléiques FAB I et de polypeptides chez un hôte. Elle concerne enfin des test diagnostics de détection de polynucléotides codant pour FAB I et de détection du polypeptide chez un hôte.
PCT/US2000/012104 1996-08-28 2000-05-04 Procedes utilisant des composes de fab i et des composes modulant l'activite de fab i WO2000070017A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000618423A JP2002544291A (ja) 1999-05-14 2000-05-04 Ｆａｂｉの使用方法
EP00935862A EP1180164A4 (fr) 1999-05-14 2000-05-04 Procedes utilisant des composes de fab i et des composes modulant l'activite de fab i
US10/888,524 US20050112713A1 (en) 1996-08-28 2004-07-09 Methods of using Fab I and compounds modulating Fab I activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13436299P 1999-05-14 1999-05-14
US60/134,362 1999-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/888,524 Continuation-In-Part US20050112713A1 (en) 1996-08-28 2004-07-09 Methods of using Fab I and compounds modulating Fab I activity

Publications (2)

Publication Number Publication Date
WO2000070017A2 WO2000070017A2 (fr) 2000-11-23
WO2000070017A3 true WO2000070017A3 (fr) 2001-02-08

Family

ID=22463029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012104 WO2000070017A2 (fr) 1996-08-28 2000-05-04 Procedes utilisant des composes de fab i et des composes modulant l'activite de fab i

Country Status (3)

Country Link
EP (1) EP1180164A4 (fr)
JP (1) JP2002544291A (fr)
WO (1) WO2000070017A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010881A (en) 1996-02-20 2000-01-04 Smithkline Beecham Corporation RibG
JP2000514308A (ja) 1996-08-16 2000-10-31 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
EP1648928A2 (fr) 2003-07-11 2006-04-26 Affinium Pharmaceuticals, Inc. Nouveaux polypeptides purifies provenant du staphylocoque dore

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826774A2 (fr) * 1996-08-28 1998-03-04 Smithkline Beecham Corporation Fab I enoyl-ACP réductase des Staphylocoques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826774A2 (fr) * 1996-08-28 1998-03-04 Smithkline Beecham Corporation Fab I enoyl-ACP réductase des Staphylocoques
JPH10174590A (ja) * 1996-08-28 1998-06-30 Smithkline Beecham Corp Ｆａｂ ｉ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGLER H. ET AL.: "Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of escherichia coli", J. BIOL. CHEM., vol. 269, no. 8, 25 February 1994 (1994-02-25), pages 5493 - 5496, XP002933508 *
See also references of EP1180164A4 *

Also Published As

Publication number Publication date
EP1180164A4 (fr) 2002-11-27
JP2002544291A (ja) 2002-12-24
EP1180164A2 (fr) 2002-02-20
WO2000070017A2 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
EP0837131A3 (fr) Composé contenant la protéine liant la fibronectine obtenu à partir de Staphylococcus
EP0837138A3 (fr) Topoisomérase III
WO2001034809A3 (fr) Acides nucleiques et proteines de staphylococcus epidermidis
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
EP0826774A3 (fr) Fab I enoyl-ACP réductase des Staphylocoques
EP0837130A3 (fr) Protéine de Streptococcus pneumoniae analogue de la protéine M
WO2003080856A3 (fr) Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
EP0837137A3 (fr) Topoisomérase III
EP0834568A3 (fr) Protéine de Streptococcus pneumoniae se liant à la salive
EP0835938A3 (fr) Topoisomérase I
WO2000070017A3 (fr) Procedes utilisant des composes de fab i et des composes modulant l'activite de fab i
EP0837136A3 (fr) Topoisomérase I
EP0845535A3 (fr) Peptidase de sequence leader (lep) de Streptococcus
WO2001029217A3 (fr) Polypeptides, et polynucleotides codant ces polypeptides
EP0843016A3 (fr) FabD (malonylCoA:ACP transacylase) de Staphylococcus
WO2003029423A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ceux-ci et procedes d'utilisation
EP0808899A3 (fr) Récepteur piégeur "Marco Scavenger" humain (HMarcoSR)
EP0843011A3 (fr) RsbU-1 dérivé de Staphylococcus
EP0839910A3 (fr) Spo-rel, homologue de relA/spoT des Staphylocoques
EP0845531A3 (fr) Polypeptides et polynucléotides de la Staphylococcus SigB opéron
EP0846766A3 (fr) Protéine de Streptococcus pneumoniae se liant à la partie Fc des IgA
EP0838523A3 (fr) RsbW-1 dérivé de Staphylococcus
EP0816502A3 (fr) Mur A-1, une UDP-N-acétylglucosamine énolpyruvyltransférase, de Streptococcus pneumoniae
EP0838524A3 (fr) RsbV-1 dérivé de Staphylococcus
WO2003085124A8 (fr) Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10009219

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000935862

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618423

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000935862

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000935862

Country of ref document: EP